Why this finding matters for families affected by LCA

Leber congenital amaurosis (LCA) is a group of inherited retinal diseases that causes severe vision impairment beginning very early in life. Although variants in NMNAT1 are an established genetic cause of LCA, the range of retinal findings associated with this gene—and the full range of disease-causing variants—continues to emerge.

A 2026 report in Ophthalmic Genetics describes a 6-year-old girl with NMNAT1-associated early-onset retinal dystrophy (EORD). Importantly, her diagnosis was not identified through an initial 330-gene inherited retinal disease (IRD) panel. It was found only after whole-genome sequencing (WGS) detected a previously unreported variant in a non-coding region of NMNAT1. The case highlights a central challenge for families seeking answers: a negative standard gene panel does not always rule out a genetic retinal condition.

An unusual clinical picture

The child in this report had nystagmus, involuntary eye movements that often begin in infancy or early childhood; esotropia, a form of inward eye turn; and reduced visual acuity. Retinal imaging revealed an atypical abnormality affecting the macula in both eyes. The macula is the central part of the retina responsible for detailed vision, such as recognizing faces and reading.

Her full-field electroretinogram (ERG), a test that measures the retina’s electrical response to light, showed borderline responses. This is notable because the combination of macular changes and borderline ERG findings did not provide a straightforward, classic pattern. NMNAT1-related disease is recognized within the LCA spectrum, but NMNAT1-associated EORD has been reported relatively rarely. This patient’s findings therefore broaden the clinical picture clinicians may consider when evaluating children with early-onset visual impairment and macular disease.

Why the first genetic test was negative

The initial IRD panel did not identify a diagnosis. Gene panels are valuable and widely used because they analyze a defined set of genes known to cause retinal disease. However, conventional testing often focuses on protein-coding portions of genes—the segments used to make proteins—and may systematically exclude many non-coding regions.

In this case, WGS identified two different NMNAT1 variants, one inherited from each parent. This is called compound heterozygosity: both copies of the gene carry a variant, but the two variants are different. Parental testing confirmed that the variants were in trans, meaning they were located on opposite copies of NMNAT1. This inheritance pattern supports an autosomal recessive NMNAT1-related disorder.

One variant was a missense change, c.480G>C (p.Leu160Phe), which changes a single amino acid in the NMNAT1 protein. The other was the newly reported c.-57+1G>C variant, located in the gene’s 5′ untranslated region (5′UTR) at a splice donor site.

The 5′UTR does not encode protein, but it is part of the RNA transcript and can be important for gene regulation and RNA processing. Splice donor sites help guide the cellular machinery that correctly joins RNA segments together. A change at such a site can disrupt normal splicing. Because this variant lies in a non-coding region that standard panels may not assess, it offers a clear example of why an important genetic finding can be missed by more limited testing approaches.

Implications for diagnosis and care

This report does not establish a new treatment, nor does it test a therapy. Its immediate importance is diagnostic. Identifying the precise genetic cause of an early-onset retinal dystrophy can end a lengthy diagnostic search, clarify the inheritance pattern within a family, and provide a more specific molecular label for the retinal condition.

The findings also support a stepwise approach when clinical suspicion for an inherited retinal disease remains high despite a negative panel result. For selected individuals—particularly those with atypical retinal imaging, early childhood onset, or a phenotype suggestive of a known IRD gene—broader genomic testing such as WGS may identify variants outside routinely analyzed coding regions.

For NMNAT1-associated disease, documenting both the retinal phenotype and the underlying variants is especially valuable. It helps distinguish the condition from other causes of childhood-onset maculopathy and contributes to the evidence needed to interpret rare or newly identified changes.

Looking ahead

This single case expands both the genetic and clinical spectrum of NMNAT1-related retinal disease. It also reinforces that the parts of the genome outside protein-coding sequences can hold clinically meaningful answers.

As genomic technologies become more comprehensive, researchers and clinical laboratories will be better positioned to identify non-coding variants, evaluate their effects, and connect them with detailed retinal findings. Continued reporting of carefully characterized cases will be essential for building that knowledge. For people with LCA or related early-onset retinal dystrophies, the study is a reminder that a negative first test may be the beginning—not the end—of the search for a genetic diagnosis.